Wells Fargo & Company Cogent Biosciences, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding COGT
# of Institutions
171Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$94 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$83 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$67.7 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$65.4 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$62.5 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $591M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...